CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
CHAMPIONS ONCOLOGY, INC.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$4.69−0.01 (-0.21%)
Close on Oct 19, 2026
- Market cap
- $65.18M
- P/E (TTM)
- –
- Dividend yield
- –
CHAMPIONS ONCOLOGY, INC. revenue by segment
By business segment
By product or service
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacology services | $14.16M | $13.20M | $16.18M | $14.52M | $13.23M | $11.35M | $11.67M | $12.50M | $13.07M | $13.12M | $11.18M | $10.88M | 92.9% | +7.0% |
| TOS data license revenue | $893.00K | $296.00K | $0 | $157.00K | $311.00K | $176.00K | $4.50M | $0 | $0 | – | $0 | – | 5.9% | +187.1% |
| Other TOS revenue | $183.00K | $335.00K | $375.00K | $363.00K | $454.00K | $831.00K | $869.00K | $991.00K | $992.00K | $886.00K | $835.00K | $697.00K | 1.2% | -59.7% |
| Personalized oncology services | – | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Champions Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.